The present invention relates generally to treatment methods using sono-responsive embolic agents and ultrasound to monitor the location or travel of the embolic agents. The embolic agents may be modified to alter wettability for enhanced treatment of various disease states.

The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

A dispensing device and cartridge for simultaneous delivery and mixing of multiple co-reactive materials, the cartridge having proximal and distal ends, and having an elongated holder body with substantially parallel longitudinal voids. Multiple syringe bodies are disposed parallel within the voids and multiple co-reactive materials are separately disposed in the syringe bodies. The dispensing device also includes a longitudinal housing which is structured and arranged to receive the cartridge and has a malleable spray or mixing tip for accessing difficult to reach locations.

A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

An adhesive composition is provided that is adapted for attachment to skin. The adhesive composition includes styrene-ethylene/butylene-styrene, polyolefin, polybutene, wax, polyacrylic acid, and an absorbent material.

An adhesive composition is provided that is adapted for attachment to skin. The adhesive composition includes styrene-ethylene/butylene-styrene, polyolefin, polybutene, wax, polyacrylic acid, and an absorbent material.

The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics.

Disclosed are terpolymer adhesives comprising three different repeating domains: a catechol containing domain, a zwitterionic domain, and a crosslinking domain. In specific examples, the polymer can contain a 3,4-dihydroxy-L-phenylalanine (DOPA) segment which contains a catechol group, a poly(sulfobetaine methacrylate) (polySBMA), and poly(ethylene glycol) dimethacrylate (PEGDMA) for light crosslinking. Alternatively, a photocleavable nitrobenzyloxycarbonyl containing crosslinker can be used. The disclosed polymers can be used as biomedical adhesives, such as to prevent leakage from the sutured intestinal tissue.

Disclosed are terpolymer adhesives comprising three different repeating domains: a catechol containing domain, a zwitterionic domain, and a crosslinking domain. In specific examples, the polymer can contain a 3,4-dihydroxy-L-phenylalanine (DOPA) segment which contains a catechol group, a poly(sulfobetaine methacrylate) (polySBMA), and poly(ethylene glycol) dimethacrylate (PEGDMA) for light crosslinking. Alternatively, a photocleavable nitrobenzyloxycarbonyl containing crosslinker can be used. The disclosed polymers can be used as biomedical adhesives, such as to prevent leakage from the sutured intestinal tissue.